DB05077ExperimentalSmall molecule
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and...
- Mechanism
- Curator reviewed
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. Clinical and preclinical studies involving this class of drug have shown that blocking the cannabinoid type 1 (CB1) receptor results in reduced food intake..
- Primary indication
- Investigated for use/treatment in obesity.Curator reviewed
- Code names
- SLV319
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with SLV319, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account